A field safety corrective action is a measure taken by the manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident associated with a product already placed on the market. The field safety notice is the communication to users or customers by which the manufacturer announces this measure. Both terms belong to the vigilance system of the MDR and IVDR.
Content of a Field Safety Corrective Action
The measure may include a recall, return to the manufacturer or supplier, replacement, technical modification, or destruction of a product. Additional maintenance information, more frequent calibration, new cleaning instructions, training, or safety-related software updates may also constitute a field safety corrective action. The common reference point is a safety risk associated with a product already placed on the market.
For implantable products, special patient observation or treatment may be part of the measure if explantation would not be medically justifiable. For IVD, the clinical measure may, for example, involve the review of previous test results, re-analysis of samples, or further patient monitoring. The field reference does not therefore exclude consequences extending to clinical care.
Purpose of the Field Safety Notice
The field safety notice is addressed to the affected users or customers and must communicate the measure without undue delay. It is not merely a cover letter accompanying a recall, but rather the communication instrument by which recipients are to recognise which product is affected, what risk exists, and what actions are expected of them.
The content of the field safety notice shall be consistent across all Member States unless a particular situation in a Member State justifies a deviation. Before publication, the draft shall in principle be submitted to the evaluating competent authority for comment, unless the urgency of the measure does not permit this. This aligns risk communication between manufacturer, authorities, and users.
An effective field measure begins with precise identification of the affected devices. This includes product designation, version, serial or batch range, distribution period, and, where applicable, assignment to countries or supply sites. The measure must also be designed to actually address the identified risk: mere information is insufficient if replacement, an update, or examination of patients is necessary.
Feedback from recipients is part of effectiveness monitoring. It shows whether hospitals, laboratories, or other users have received, understood, and implemented the notice. If confirmations are absent or further incidents occur despite the measure, the manufacturer must assess whether the scope, content, or target group of the field measure needs to be adjusted.
Authority notification and user notification serve different functions. The authority can assess the appropriateness of the planned risk control, while the field safety notice contains actionable instructions for the site where the product is used. Both communication channels must be consistent in essential facts.
Distinction from Commercial Recalls
A recall for purely commercial reasons is not a field safety corrective action. Delisting, model change, or distribution decisions are insufficient if they are not aimed at preventing or reducing the risk of a serious incident. The decisive factor is therefore not the physical retrieval alone, but its technical or medical safety purpose.
Likewise, not every product modification on the market is a field safety corrective action. A routine improvement unrelated to a serious risk is not communicated by a field safety notice. However, once a modification becomes necessary to limit an identified risk in products already placed on the market, the vigilance logic applies.
Relevance for clinical trials
A field measure may directly affect ongoing clinical investigations if investigational sites or participants are using products of the same design, batch, or software version. The sponsor must then assess whether investigational products must be blocked, replaced, or used with modified instructions, and whether the protocol, informed consent, or risk assessment must be adapted. Documentation of recipients and implementation at the investigational site is critical for traceability.
Full-service CROs such as Mediconomics support impact analysis for ongoing investigations, communication with investigational sites, and tracking of confirmations to field safety notices. They coordinate monitoring, regulatory affairs, and safety management so that modifications to investigational products, training, or patient measures are consistently reflected in study documentation and safety data.
Frequently Asked Questions (FAQ)
Is a software rollback a field safety corrective action?
Yes, if the reversion to an earlier version prevents a safety-related error in a product already placed on the market or reduces its risk.
What is the purpose of the field safety notice?
It informs the affected users or customers of the specific safety measure and the steps they are required to take.
Is a voluntary product recall always an FSCA?
No. Without a technical or medical purpose to limit a serious risk, there is no field safety corrective action.
Regulatory References
- Regulation (EU) 2017/745, Article 2 numbers 68 and 69 – defines FSCA and field safety notice for medical devices.
- Regulation (EU) 2017/746, Article 2 numbers 71 and 72 – contains the corresponding terms for IVD.
- Regulation (EU) 2017/745, Article 89 – governs the analysis of serious incidents and field measures.
- MDCG 2023-3 Rev.2 – explains examples, communication, and authority dialogue on FSCAs.